Cardiff Oncology, Inc. ( (CRDF) ) has released its Q3 earnings. Here is a breakdown of the information Cardiff Oncology, Inc. presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Cardiff Oncology, Inc. is a clinical-stage biotechnology company based in San Diego, California, focusing on developing novel cancer therapies through Polo-like Kinase 1 inhibition. The latest earnings report for the quarter ending September 30, 2025, highlights a decrease in revenues and an increase in net losses compared to the previous year. Key financial metrics include a net loss of $11.3 million for the quarter and $38.7 million for the nine months, with research and development expenses rising due to ongoing clinical trials. The company continues to focus on its lead drug candidate, onvansertib, which is being tested in various cancer indications. Despite the financial challenges, Cardiff Oncology remains committed to advancing its clinical programs and exploring strategic opportunities to enhance its pipeline.